PARP1 and ovarian carcinoma: Indeed, despite their clinical efficacy in HGSOC with deficiencies in HR, PARP inhibitors have also been found to be effective in HGSOC patients without BRCA loss-of function mutations or homologous recombination deficiency as determined by last generation genomic sequencing [3, 4] and the FDA and EMA (European Medicines Agency) have recently broadened the approval of PARPi as maintenance monotherapy for ovarian cancer patients independently of BRCA or HR status [21].